VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (bsADC) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb. The company confirmed that OmniAb has successfully completed its discovery work, allowing the program to transition into its next development phase. VXA-222 is designed to target two tumor antigens simultaneously using an “AND-gate” approach, which is intended to improve precision in treating solid tumors by reducing off-target effects.
The collaboration, which began in May 2025, leverages OmniAb’s antibody discovery technologies, including the OmniClic platform, combined with VERAXA’s proprietary linker technology and conjugation expertise. Under the agreement, VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, while OmniAb is entitled to a share of specified revenue from resulting products. This milestone marks a significant step forward for VERAXA’s pipeline, which focuses on next-generation antibody-based therapeutics.
The advancement of VXA-222 is particularly important as it represents a novel approach to cancer treatment. Bispecific ADCs that employ an AND-gate logic are designed to activate only when both target antigens are present, potentially increasing tumor specificity and reducing damage to healthy tissues. This could address a major challenge in oncology: the narrow therapeutic window of many existing ADCs. The successful completion of OmniAb’s discovery work suggests that the lead candidate has met preclinical criteria for moving forward, though further validation will be needed.
For VERAXA, this milestone underscores the progress of its broader strategy to build a premier engine for antibody-based therapeutics. The company’s pipeline includes bispecific T cell engagers and other innovative formats, all powered by technologies originating from the European Molecular Biology Laboratory. The BiTAC format, a registered trademark, is among the platforms being advanced toward clinical development.
The implications of this announcement extend beyond VERAXA’s corporate progress. If VXA-222 succeeds in clinical trials, it could validate the AND-gate approach for bispecific ADCs, potentially opening new avenues for treating solid tumors that are currently difficult to target. The collaboration with OmniAb also highlights the growing trend of leveraging specialized platforms to accelerate drug discovery, as smaller biotechs partner with technology providers to access advanced capabilities without building them in-house.
Investors and industry observers will be watching for further updates on VXA-222’s development, including IND-enabling studies and eventual clinical trial initiation. The company’s forward-looking statements, as detailed in its SEC filings, remind stakeholders of the inherent risks and uncertainties in drug development. However, this milestone provides a tangible sign of progress for VERAXA’s pipeline and its collaborative model.
For more information, the full press release is available at https://ibn.fm/qMRuJ. Additional updates on VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.
